Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study

References

• Honda T, Kabashima K. Reconciling innate and acquired immunity in atopic dermatitis. J Allergy Clin Immunol. 2020;145(4):1–7. doi: 10.1016/j.jaci.2020.02.008.
   PubMed Web of Science ®Google Scholar
• Nakajima S, Tie D, Nomura T, et al. Novel pathogenesis of atopic dermatitis from the view of cytokines in mice and humans. Cytokine. 2021;148:155664. doi: 10.1016/j.cyto.2021.155664.
   PubMed Web of Science ®Google Scholar
• Uchida H, Kamata M, Egawa S, et al. Newly developed erythema and red papules in the face and neck with detection of demodex during dupilumab treatment for atopic dermatitis improved by discontinuation of dupilumab, switching to upadacitinib or treatment with oral ivermectin: a report of two cases. J Eur Acad Dermatol Venereol. 2023;37(3):e300–e302. doi: 10.1111/jdv.18743.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047–1055. doi: 10.1001/jamadermatol.2021.3023.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168. doi: 10.1016/S0140-6736(21)00588-2.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877–884. doi: 10.1016/j.jaci.2019.11.025.
   PubMed Web of Science ®Google Scholar
• Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–2181. doi: 10.1016/S0140-6736(21)00589-4.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Cohen SB, Winthrop KL, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9(1):e002735. doi: 10.1136/rmdopen-2022-002735.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Ladizinski B, Prajapati VH, et al. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (heads up). J Am Acad Dermatol. 2023;89(3):478–485. doi: 10.1016/j.jaad.2023.05.033.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, de Bruin-Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD up study results. J Allergy Clin Immunol. 2022;149(3):977–987.e14. doi: 10.1016/j.jaci.2021.07.036.
   PubMed Web of Science ®Google Scholar
• Paller AS, Ladizinski B, Mendes-Bastos P, et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the measure up 1, measure up 2, and AD up randomized clinical trials. JAMA Dermatol. 2023;159(5):526–535. doi: 10.1001/jamadermatol.2023.0391.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Thyssen JP, Silverberg JI, et al. Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies. J Allergy Clin Immunol. 2023;151(1):172–181. doi: 10.1016/j.jaci.2022.09.023.
   PubMed Web of Science ®Google Scholar
• Katoh N, Ohya Y, Murota H, et al. Safety and efficacy of upadacitinib for atopic dermatitis in Japan: 2-year interim results from the phase 3 rising up study. Dermatol Ther. 2023;13(1):221–234. doi: 10.1007/s13555-022-00842-7.
   PubMed Web of Science ®Google Scholar
• Thyssen JP, Thaçi D, Bieber T, et al. Upadacitinib for moderate-to-severe atopic dermatitis: stratified analysis from three randomized phase 3 trials by key baseline characteristics. J Eur Acad Dermatol Venereol. 2023;37(9):1871–1880. doi: 10.1111/jdv.19232.
   PubMedGoogle Scholar
• Kosaka K, Uchiyama A, Ishikawa M, et al. Real-world effectiveness and safety of upadacitinib in japanese patients with atopic dermatitis: a two-centre retrospective study. Eur J Dermatol. 2022;32(6):800–802. doi: 10.1684/ejd.2022.4365.
   PubMed Web of Science ®Google Scholar
• Tran V, Ross G. A real-world Australian experience of upadacitinib for the treatment of severe atopic dermatitis. Australas J Dermatol. 2023;64(4):e352–e356.
   PubMed Web of Science ®Google Scholar
• Schlösser AR, Boeijink N, Olydam J, et al. Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort. J Eur Acad Dermatol Venereol. 2024;38(2):384–392. doi: 10.1111/jdv.19581.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Fujimoto E, et al. The differential effects of upadacitinib treatment on skin rashes of four anatomical sites in patients with atopic dermatitis. J Dermatolog Treat. 2023;34(1):2212095.
   PubMed Web of Science ®Google Scholar
• Hagino T, Yoshida M, Hamada R, et al. Therapeutic effectiveness of upadacitinib on individual types of rash in Japanese patients with moderate-to-severe atopic dermatitis. J Dermatol. 2023;50(12):1576–1584. doi: 10.1111/1346-8138.16950.
   PubMed Web of Science ®Google Scholar
• Hagino T, Yoshida M, Hamada R, et al. Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan. J Dermatolog Treat. 2023;34(1):2276043.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Kanda N. The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2022;49(11):1158–1167. doi: 10.1111/1346-8138.16549.
   PubMed Web of Science ®Google Scholar
• Licata G, Tancredi V, Calabrese G, et al. Atopic dermatitis and difficult-to-treat areas: a case series of four patients with dupilumab-resistant primary atopic blepharitis and successfully treated with upadacitinib. Dermatitis. 2023. doi: 10.1089/derm.2023.0196.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Ortoncelli M, Schena D, et al. Long-term effectiveness and safety of upadacitinib for atopic dermatitis in a real-world setting: an interim analysis through 48 weeks of observation. Am J Clin Dermatol. 2023;24(6):953–961. doi: 10.1007/s40257-023-00798-0.
   PubMed Web of Science ®Google Scholar
• Saeki H, Ohya Y, Furuta J, et al. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021. Allergol Int. 2022;71(4):448–458. doi: 10.1016/j.alit.2022.06.009.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol. 2022;158(4):404–413. doi: 10.1001/jamadermatol.2022.0029.
   PubMed Web of Science ®Google Scholar
• Norlin JM, Nilsson K, Persson U, et al. Complete skin clearance and psoriasis area and severity index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals. Br J Dermatol. 2020;182(4):965–973. doi: 10.1111/bjd.18361.
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–326. doi: 10.1056/NEJMoa2109927.
   PubMed Web of Science ®Google Scholar